Iovance Biotherapeutics (IOVA) Financials: History & Chart

Iovance Biotherapeutics, Inc.(IOVA)

Biotechnology · San Carlos, CA

$13.12-1.03 (-7.28%)

Delayed quote: Oct 6, 2026, 3:10 PM EDT

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

San Carlos, CA

975 employees

www.iovance.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Frederick G. Vogt

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	324.97M	99.31M	71.43M	86.77M	67.45M	59.95M	49.32M	73.69M	58.55M
Cost of Goods Sold	-52.97M	45.13M	1.02M	-100.53M	1.41M	56.66M	49.74M	45.54M	39.82M
Gross Profit	377.94M	54.18M	70.41M	187.30M	66.05M	3.29M	-417K	28.15M	18.73M
Gross Profit Margin	116.3%	54.6%	98.6%	215.9%	97.9%	5.5%	-0.8%	38.2%	32.0%
Total Operating Expenses	679.25M	106.09M	151.45M	260.76M	160.95M	117.06M	120.80M	114.73M	107.80M
Research & Development	270.44M	63.93M	62.49M	68.85M	75.17M	79.36M	76.88M	72.22M	68.25M
Selling, General & Administrative	109.65M	0.00	38.95M	36.14M	34.55M	37.70M	43.92M	42.50M	39.55M
Operating Income (EBIT)	-301.31M	-51.91M	-81.04M	-73.46M	-94.90M	-113.77M	-121.22M	-86.58M	-89.07M
Operating Margin	-92.7%	-52.3%	-113.5%	-84.7%	-140.7%	-189.8%	-245.8%	-117.5%	-152.1%
Income Before Tax (EBT)	-293.78M	-48.69M	-79.71M	-71.72M	-93.66M	-109.67M	-118.00M	-77.00M	-85.06M
Interest Income	8.66M	N/A	1.33M	7.32M	N/A	4.10M	3.22M	9.57M	4.00M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	7.53M	3.22M	1.33M	1.74M	1.24M	4.10M	3.22M	9.57M	4.00M
Net Income	-289.52M	-47.31M	-79.05M	-71.90M	-91.25M	-111.66M	-116.16M	-78.56M	-83.54M
Income Tax Expense	-4.26M	-1.37M	-665K	184K	-2.40M	1.99M	-1.84M	1.56M	-1.52M
Net Profit Margin	-89.1%	-47.6%	-110.7%	-82.9%	-135.3%	-186.2%	-235.5%	-106.6%	-142.7%
EBITDA	-270.33M	-42.41M	-72.50M	-69.53M	-85.89M	-101.84M	-110.16M	-74.89M	-77.92M
EBITDA Margin	-83.2%	-42.7%	-101.5%	-80.1%	-127.3%	-169.9%	-223.3%	-101.6%	-133.1%
Depreciation & Amortization	30.98M	9.50M	8.54M	3.93M	9.01M	11.94M	11.06M	11.69M	11.15M
EPS Basic	-0.70	-0.11	-0.19	-0.15	-0.25	-0.33	-0.36	-0.26	-0.28
EPS Diluted	-0.70	-0.11	-0.19	-0.15	-0.25	-0.33	-0.36	-0.26	-0.28
Weighted Average Basic Shares	450.19M	450.19M	418.51M	406.97M	364.04M	334.51M	322.87M	304.89M	303.27M
Weighted Average Diluted Shares	450.19M	450.19M	418.51M	406.97M	364.04M	334.51M	322.87M	304.89M	303.27M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	263.50M	164.07M	1.19M	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	7.29M	124.00M	10.76M	0.00	0.00	0.00	8.12M	956K
Gross Profit	256.22M	40.08M	-9.57M	0.00	0.00	0.00	-8.12M	-956K
Gross Profit Margin	97.2%	24.4%	-804.5%	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	659.57M	435.35M	450.99M	398.88M	342.70M	261.94M	206.87M	128.26M
Research & Development	300.27M	282.34M	344.08M	294.78M	259.04M	201.73M	166.02M	99.83M
Selling, General & Administrative	152.32M	153.02M	106.92M	104.10M	83.66M	60.21M	40.85M	28.43M
Operating Income (EBIT)	-403.36M	-395.28M	-460.56M	-398.88M	-342.70M	-261.94M	-206.87M	-128.26M
Operating Margin	-153.1%	-240.9%	-38735.0%	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-393.05M	-375.00M	-447.52M	-395.89M	-342.25M	-259.58M	-197.56M	-123.58M
Interest Income	N/A	20.27M	13.04M	2.98M	451K	2.36M	9.32M	N/A
Interest Expense	N/A	N/A	N/A	2.98M	N/A	N/A	N/A	N/A
Other Income/Expense	10.31M	20.27M	13.04M	2.98M	451K	2.36M	9.32M	4.68M
Net Income	-390.98M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M	-197.56M	-123.58M
Income Tax Expense	-2.07M	-2.83M	-3.48M	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-148.4%	-226.8%	-37345.4%	N/A	N/A	N/A	N/A	N/A
EBITDA	-367.42M	-351.67M	-427.43M	-377.74M	-328.72M	-260.80M	-198.75M	-127.30M
EBITDA Margin	-139.4%	-214.3%	-35948.9%	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	35.94M	43.61M	33.13M	21.14M	13.98M	1.14M	8.12M	956K
EPS Basic	-1.09	-1.28	-1.89	-2.49	-2.23	-1.88	-1.50	-1.27
EPS Diluted	-1.09	-1.28	-1.89	-2.49	-2.23	-1.88	-1.50	-1.27
Weighted Average Basic Shares	357.35M	289.88M	235.13M	159.26M	153.41M	138.30M	124.34M	97.28M
Weighted Average Diluted Shares	357.35M	289.88M	235.13M	159.26M	153.41M	138.30M	124.34M	97.28M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.